RM-MET / Metabolic and incretin signalling
Dulaglutide
Also known as: LY2189265 · GLP-1 receptor agonist Fc-fusion protein
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Dulaglutide links a modified GLP-1 analog to an IgG4 Fc fragment. Its structure, expression and quality controls differ materially from those of a short synthetic peptide.
Evidence position
An FDA-labeled comparator plus controlled human studies support Grade A for the regulated presentation.
What the record does not establish
A familiar molecule name does not show that another material matches the fusion structure or the finished product.
Sources
- 01Trulicity prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. label for the finished fusion-biologic product
- Does not show
- Does not qualify separately manufactured material
- 02Dulaglutide versus liraglutide: AWARD-6PubMed
- Shows
- Randomized phase 3 comparative human trial
- Does not show
- Applies to defined clinical products and protocol
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine / 2025 Dec 18PMID 41406444 / DOI 10.1056/NEJMoa2505928
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.The lancet. Diabetes & endocrinology / 2018 AprPMID 29397376 / DOI 10.1016/S2213-8587(18)30024-X
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) / 2023 Aug 5PMID 37369232 / DOI 10.1016/S0140-6736(23)01302-8
- Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.The Journal of clinical endocrinology and metabolism / 2021 Jan 23PMID 33236115 / DOI 10.1210/clinem/dgaa863
- Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.The lancet. Diabetes & endocrinology / 2022 SepPMID 35914543 / DOI 10.1016/S2213-8587(22)00188-7
CLINICALTRIALS.GOV / FOUND RECORDS
- A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaCOMPLETED / PHASE4 / Eli Lilly and CompanyNCT05659537 / DIRECT intervention MATCH: Dulaglutide
- A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 DiabetesCOMPLETED / PHASE1 / Eli Lilly and CompanyNCT05377333 / DIRECT intervention MATCH: Dulaglutide
- A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes MellitusCOMPLETED / PHASE3 / Eli Lilly and CompanyNCT01584232 / DIRECT intervention MATCH: Dulaglutide
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)RECRUITING / PHASE3 / Eli Lilly and CompanyNCT06739122 / DIRECT intervention MATCH: Dulaglutide
- A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusCOMPLETED / PHASE3 / CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT06235086 / DIRECT intervention MATCH: Dulaglutide